DHR
Danaher Corporation224.70
-3.83-1.68%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms guide, details upsides
Q&A reaffirmed the 3-6% core growth guide with segment details—high single-digit bioprocessing (consumables upper-end high single digits, equipment flat), flat life sciences, low single-digit diagnostics—while flagging upsides from life sciences end-market recovery and bioprocessing acceleration. Management cautioned one quarter of equipment growth isn't a trend yet, despite three quarters of sequential order gains and book-to-bill near 1 on consumables. Cost actions deliver $250M savings for 30¢ EPS lift, mainly H2; M&A setup improves with lower valuations. Abcam shows three months of growth, margins up 500bps post-acquisition. Encouraged tone, but investors watch biotech funding flow-through.
Key Stats
Market Cap
160.90BP/E (TTM)
46.33Basic EPS (TTM)
4.85Dividend Yield
0.01%Recent Filings
10-K
FY2025 results
Danaher's FY2025 sales rose 3% to $24.6B with 2% core growth, driven by 8% Biotechnology sales increase (6.5% core) from bioprocessing consumables while Life Sciences core sales fell 1.5% on funding weakness. Operating profit margins slipped 130bps to 19.1% due to $562M impairments across segments, yet Diagnostics held steady at 26.7%. Net earnings from continuing operations dipped to $3.6B ($5.03 diluted EPS) from $3.9B ($5.29). Debt climbed to $18.4B with $4.6B cash; $3.1B share repurchases. Q4 accelerated core growth in Biotechnology. Tariffs added <$300M costs, offset by productivity. Pending Masimo acquisition eyed for Diagnostics. Global economic conditions risk quarterly momentum.
8-K
Danaher to buy Masimo
Danaher inked a deal on February 16, 2026, to snap up Masimo for $180 per share in cash, totaling ~$9.9B enterprise value. Masimo slots into Diagnostics as a standalone unit, promising high-single-digit core growth and $0.15-$0.20 EPS accretion in year one. Deal awaits antitrust nods and Masimo votes. Regulatory hurdles loom large.
8-K
Danaher's strong 2025 finish
Danaher capped 2025 with Q4 revenues up 4.5% to $6.8B and full-year sales rising 3.0% to $24.6B, driven by 6.0% core growth in Biotechnology while Life Sciences lagged. Non-GAAP adjusted EPS hit $7.80, up 4.5%, with free cash flow at $5.3B. Biotech shone. Guides 2026 core revenue growth of 3-6% and EPS $8.35-$8.50.
8-K
Q4 revenues up mid-single digits
Danaher previewed Q4 2025 results ahead of its J.P. Morgan Healthcare Conference talk, with revenues up mid-single digits year-over-year and non-GAAP core growth hitting the high end of prior low-single digit guidance. Full-year adjusted EPS nears the top of $7.70-$7.80. Bioprocessing stayed strong; Life Sciences and Diagnostics beat expectations. Execution delivered.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
DGX
Quest Diagnostics Incorporated
178.66-5.45
ILMN
Illumina, Inc.
131.56-3.36
QGEN
Qiagen N.V.
45.01-0.43
TECH
Bio-Techne Corp
57.44-1.25
TMO
Thermo Fisher Scientific Inc
570.16-5.75
WAT
Waters Corporation
378.53-6.89